Big coffee interview with Professor Wang Jing: Application of Circulating Tumor DNA in Lymphoma

Accurate diagnosis and early screening can effectively prolong the survival time of patients with malignant tumors and improve the cure rate of patients
.

With the development of molecular biology, circulating tumor DNA (ctDNA), as a kind of cell-free DNA derived from tumors, may carry the same oncogenic mutations and genetic changes as the primary tumor, and is expected to be used as a non-invasive monitoring biomarker for cancer.
Things
.

The emergence of ctDNA has promoted the development of liquid biopsy technology for cancer diagnosis, prognosis evaluation, curative effect monitoring, and genetic/epigenetic abnormality research, and has considerable application space in the field of lymphoma
.

From July 3 to 4, 2021, the 3rd Hematological Tumor Accurate Detection Summit Forum was successfully held in Beijing
.

During this period, Yimaitong specially invited Professor Wang Jing from Peking University Third Hospital to share the latest development of ctDNA technology and its application in lymphoma
.

Yimaitong: ctDNA is a molecular level tumor monitoring method, and it is also one of the research hotspots in recent years
.

Could you please talk about the value of ctDNA in the diagnosis, treatment, progress monitoring and prognosis prediction of lymphoma? Professor Wang Jing ctDNA, as a molecular marker, is one of the main research objects in liquid biopsy technology.
It has a strong prompting effect on diseases and is currently mainly used for preclinical research
.

ctDNA is of great significance for the diagnosis, treatment, prognosis assessment and disease course monitoring of patients
.

For diagnosis, taking T-cell lymphoma as an example, ctDNA can detect specific gene mutations in angioimmunoblastic lymphoma (AITL) (such as: RHOA G17V and IDH2), which plays an important role in pathological diagnosis; , CtDNA can detect the specific target of the target drug, and the clinic can select the targeted drug suitable for the patient according to the result, avoiding the potential drug resistance; in the prognostic evaluation, the gene mutation of the initial tumor cell detected by ctDNA can indicate Prognosis, such as TP53 gene mutations can indicate a poor prognosis; in monitoring the course of the disease, ctDNA can detect disease recurrence earlier than imaging with higher sensitivity
.

Yimaitong: In view of the value of ctDNA, could you please talk about the application prospect of this test? Will it replace the existing detection technology? Professor Wang Jing's liquid biopsy technology based on ctDNA is a detection method that complements the existing detection technology, which can effectively improve the acceptance of molecular testing by patients and help to have a comprehensive understanding of the disease
.

For patients, ctDNA is a non-invasive detection method.
Only peripheral blood is drawn from patients.
The test specimens are easy to obtain and easy for patients to accept.
For diseases, due to limited tumor biopsy sites, it is useful for the diagnosis of systemic tumors, especially lymphoma Certain limitations, and ctDNA can detect the DNA in the peripheral blood of the whole body, which can reflect more extensive and comprehensive data
.

However, it needs to be pointed out that the current quantification and detection sensitivity of ctDNA still need to be improved, which is an urgent problem to be solved in the next step
.

Conclusion As a non-invasive tumor biomarker, ctDNA has good application prospects in tumor diagnosis, prognosis, and response to treatment monitoring
.

Although the current ctDNA detection still has certain limitations, the value of this technology in the diagnosis, treatment and prognosis of lymphoma has gradually emerged.
It is believed that in the near future, the development of ctDNA-based liquid biopsy technology will be a diagnostic and treatment belt for lymphoma.
Here comes a new chapter
.

Professor Wang Jing, leader of the molecular group of the Department of Hematology, Peking University Third Hospital, and a master of medicine.
He is mainly engaged in basic and clinical research related to lymphoma and other hematological malignancies.
Main research direction: B7 molecule anti-tumor and immune tolerance role, lymphoma, myeloma and leukemia pathogenesis, prognosis factors, hematologic malignancies immune cell therapy
.

Participated in the National Natural Science Foundation of China, Beijing Natural Science Foundation, Peking University Cancer Research Center "985 Center Research", 211 Fund and other research funds, and won the Scientific Research Outstanding Achievement Award (Science and Technology) Science and Technology Progress Award of Higher Education Institutions Second prize, published more than 70 articles, participated in the compilation and translation of 5 works
.

Poke "read the original text", we make progress together